

Amendments to the Claims under Revised 37 C.F.R. § 1.121

Claim 1 (previously amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence as set forth in any of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, residues 4 through 549 of SEQ ID NO: 9, residues 4 through 519 of SEQ ID NO: 15, or residues 4 through 516 of SEQ ID NO: 19.

Claim 2 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 9.

Claim 3 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 15.

Claim 4 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 19.

Claim 5 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 5.

Claim 6 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 7.

Claim 7 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 13.

Claim 8 (previously amended): The method of Claim 1, wherein the nucleic acid molecule

comprises the nucleotide sequence as set forth in SEQ ID NO: 11.

Claim 9 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 17.

Claim 10 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 549 of the nucleotide sequence as set forth in SEQ ID NO: 9.

Claim 11 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 519 of the nucleotide sequence as set forth in SEQ ID NO: 15.

Claim 12 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 516 of the nucleotide sequence as set forth in SEQ ID NO: 19.

Claim 13 (previously amended): The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 3.

Claim 14 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.

Claim 15 (previously amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20; and
wherein said polypeptide has:

- a) at least one conservative amino acid substitution;
- b) at least one amino acid substitution at a glycosylation site;
- c) at least one amino acid substitution at a proteolytic cleavage site;
- d) at least one amino acid substitution at a cysteine residue;
- e) at least one amino acid deletion;
- f) at least one amino acid insertion;
- g) a C- and/or N-terminal truncation; or
- h) a combination of modifications selected from the group consisting of conservative

amino acid substitutions, amino acid substitutions at a glycosylation site, amino acid substitutions at a proteolytic cleavage site, amino acid substitutions at a cysteine residue, amino acid deletions, amino acid insertions, C-terminal truncation, and N-terminal truncation.

Claim 16 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one conservative amino acid substitution.

Claim 17 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a glycosylation site.

Claim 18 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a proteolytic cleavage site.

Claim 19 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a cysteine residue.

Claim 20 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid deletion.

Claim 21 (previously amended): The method of Claim 15, wherein said encoded polypeptide has at least one amino acid insertion.

Claim 22 (previously amended): The method of Claim 15, wherein said encoded polypeptide has a C- and/or N-terminal truncation.

Claim 23 (previously amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20.

Claim 24 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 10.

Claim 25 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 16.

Claim 26 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 20.

Claim 27 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 6.

Claim 28 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 8.

Claim 29 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 14.

Claim 30 (previously amended): The method of Claim 23, wherein said encoded polypeptide

comprises the amino acid sequence as set forth in SEQ ID NO: 12.

Claim 31 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 18.

Claim 32 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 183 of the amino acid sequence as set forth in SEQ ID NO: 10.

Claim 33 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 173 of the amino acid sequence as set forth in SEQ ID NO: 16.

Claim 34 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 172 of the amino acid sequence as set forth in SEQ ID NO: 20.

Claim 35 (previously amended): The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

Claim 36 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

Claim 37 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4 or a C- and/or N-terminally shortened sequence thereof.

Claim 38 (original): The method of Claim 37, wherein said polypeptide further comprises an amino-terminal methionine.

Claim 39 (original): The method of Claim 37, wherein said polypeptide comprises a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4.

Claim 40 (original): The method of Claim 39, wherein said polypeptide further comprises an amino-terminal methionine.

Claim 41 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4.

Claim 42 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is nonglycosylated or is glycosylated by a CHO cell, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claim 43 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide consists of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4.

Claim 44 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide consists of a C-terminally shortened sequence of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Ca Claim 45 (currently amended): The method of either Claims 15 or ~~34~~ 23, wherein said

CR polypeptide has at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and the carboxyl-terminus.

Claim 46 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the amino-terminus.

Claim 47 (original): The method of Claim 46, wherein said polypeptide has a methionine at the amino-terminus.

Claim 48 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the carboxyl-terminus.

CR Claim 49 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is encoded by a nucleic acid ~~which~~ that hybridizes ~~under moderately or highly stringent conditions~~ to the complement of the nucleic acid molecule ~~defined in of~~ Claim 1 at 65°C in a hybridization buffer comprising 6x SSC, 5X Denhardt's, and 0.1% SDS.

Claim 50 (original): The method of any of Claims 1, 15, or 23, wherein said polypeptide is chemically derivatized.

Claim 51 (original): The polypeptide of any of Claims 1, 14, 15, 23, 36, 37, 41, 42, 43, 44, or 49, wherein said polypeptide is not glycosylated.

Claim 52 (original): The polypeptide of any of Claims 1, 14, 15, 23, 36, 37, 41, 42, 43, 44, or 49, wherein said polypeptide is glycosylated.

Claim 53 (original): The polypeptide of Claim 52, wherein said polypeptide is glycosylated by a CHO cell.

Claim 54 (original): The method of any of Claims 1, 15, or 23, wherein said recombinant polypeptide is expressed in a cultured cell *in vitro* and said recombinant polypeptide is isolated therefrom.

Claim 55 (original): The method of Claim 54, wherein the cultured cell is a non-human cell.

C4 Claim 56 (currently amended): The method of Claim 55, wherein the non-human cell ~~line~~ is a prokaryotic cell.

Claim 57 (original): The method of Claim 56, wherein the prokaryotic cell is *Escherichia coli*.

C5 Claim 58 (currently amended): The method of Claim 55, wherein the non-human cell ~~line~~ is a eukaryotic cell.

Claim 59 (original): The method of Claim 58, wherein the eukaryotic cell is a mammalian cell.

Claim 60 (original): The method of Claim 59, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 61 (original): The method of Claim 54, wherein the polypeptide is glycosylated.

Claim 62 (original): The method of Claim 54, wherein the polypeptide is not glycosylated.